[{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Topical Cream","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"EPI Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Topical Cream","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Sato Yakuhin Kogyo Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Luliconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Sato Yakuhin Kogyo Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sato Yakuhin Kogyo Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sato Yakuhin Kogyo Co., Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sato Yakuhin Kogyo Co., Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The collaboration aims to enable Sato to concentrate on the development, manufacturing, and commercialization of topical Zoryve (roflumilast) in Japan. It is used in the treatment of Plaque Psoriasis.

                          Product Name : Zoryve

                          Product Type : Other Small Molecule

                          Upfront Cash : $25.0 million

                          February 28, 2024

                          Lead Product(s) : Roflumilast

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : Arcutis Biotherapeutics

                          Deal Size : $40.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...

                          Product Name : Rhofade

                          Product Type : Other Small Molecule

                          Upfront Cash : $5.0 million

                          December 21, 2022

                          Lead Product(s) : Oxymetazoline Hydrochloride

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved FDF

                          Recipient : EPI Health

                          Deal Size : $7.5 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 08, 2021

                          Lead Product(s) : Luliconazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank